AZD 3759

Next Previous
Drug Profile

AZD 3759

Alternative Names: AZD-3759; EGFR antagonist - AstraZeneca; Epidermal growth factor receptor tyrosine kinase inhibitor - AstraZeneca

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Amines; Antineoplastics; Piperazines; Quinazolines
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Second-line therapy or greater) in South Korea (PO)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Second-line therapy or greater) in USA (PO)
  • 30 Oct 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease) in China (PO) (NCT03360929)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top